## Review setup
- **Input scope** Full manuscript text (abstract, introduction, results, discussion, materials and methods, conclusions) as provided
- **Assessment boundary** Scientific content, experimental design, data interpretation, and claims as presented in the provided text; no external data or supplementary materials were available for verification
- **Shared manuscript claim summary** The authors report that the plastoquinone analog PQ2 shows superior antiproliferative activity against the HCT-116 colorectal cancer cell line compared to analogs PQ3 and PQ10, induces apoptosis, binds to DNA in silico, and possesses favorable predicted pharmacokinetic properties, suggesting its potential as an orally bioavailable drug-like candidate for colorectal cancer treatment
- **Visible evidence base** One-dose NCI 60-cell-line screening data (reported as percent growth inhibition), MTT assay IC50 values for PQ2 and cisplatin, annexin V/ethidium homodimer III apoptosis data, molecular docking results against DNA (PDB ID 2GWA), and in silico ADME predictions
- **Missing materials affecting confidence** Raw data tables for NCI screening (only selected values reported), full dose-response curves for MTT assays, statistical analysis details (number of replicates, error bars, statistical tests used), apoptosis quantification methodology and representative images, docking validation parameters (e.g., RMSD, pose analysis), compound purity and characterization data, and details of ADME prediction software parameters

## Reviewer
- **Overall assessment** The manuscript presents a straightforward extension of previously reported work on plastoquinone analogs, focusing on one compound (PQ2) in a single colorectal cancer cell line. While the topic is of potential interest to the natural product and anticancer drug discovery community, the study is limited in scope, lacks mechanistic depth, and contains several claims that are not fully supported by the presented evidence. The in silico docking and ADME predictions are preliminary and would benefit from experimental validation. The manuscript would be strengthened by additional cell lines, normal cell controls, mechanistic studies, and more rigorous statistical reporting.
- **Who would be interested in the results, and why** Researchers in natural product-based drug discovery, medicinal chemistry, and colorectal cancer pharmacology may find interest in the identification of PQ2 as a potential lead compound. The study also speaks to the broader theme of derivatizing plant products to improve anticancer activity, which is relevant to those working on quinone-based therapeutics.
- **Major strengths** The study addresses a clinically relevant cancer type with an unmet need for new therapeutic agents. The selection of compounds is based on a rational structure-activity relationship approach from prior work. The inclusion of NCI 60-cell-line screening provides a broad initial assessment of antiproliferative activity. The combination of in vitro and in silico methods is a reasonable preliminary approach for compound evaluation.
- **Major Concerns** See detailed items below.
- **Minor Comments** See detailed items below.
- **Technical failings that need to be addressed before the case is established** R1-M1 (single cell line), R1-M2 (lack of statistical rigor), R1-M3 (docking claims overinterpreted), R1-M4 (apoptosis data incomplete), R1-M5 (ADME predictions not validated)
- **Assessment against Nature-style criteria**  
  *Originality*: Limited. The study is an incremental extension of the authors' own prior publications on the same compound series. The claim of being the "first study showing anti-colorectal cancer activity of PQ analogs" is not substantiated with a comprehensive literature search and is a weak basis for originality.  
  *Scientific importance*: Moderate at best. The findings are preliminary and do not establish a clear therapeutic advantage over existing agents. The mechanistic insight is superficial.  
  *Interdisciplinary readership*: Narrow. The work is primarily of interest to medicinal chemists and cancer biologists working on quinone derivatives. The lack of depth in any single discipline limits broader appeal.  
  *Technical soundness*: The experimental methods are standard, but the reporting is incomplete. Statistical analyses are missing, and the docking study lacks validation. The conclusions drawn exceed what the data can support.  
  *Readability for nonspecialists*: The manuscript is generally readable, but the introduction and discussion assume familiarity with quinone chemistry and cancer biology. Some sections, particularly the docking description, are technical.
- **Recommendation posture** Currently not established from the provided evidence. The core claims regarding the therapeutic potential of PQ2 for colorectal cancer are not sufficiently supported by the data presented. Major revisions and additional experiments are required before the case can be made.

### Major Concerns

- **Concern ID** R1-M1
- **Severity** Major
- **Blocking** Yes
- **Axis** Experimental scope and generalizability
- **Claim pointer** The authors claim that PQ2 is effective in colorectal cancer treatment based on studies in a single cell line (HCT-116).
- **Evidence pointer** Section 2.1.2, Section 2.1.3, Section 3
- **Concern** The entire therapeutic claim for colorectal cancer rests on experiments performed in only one cell line (HCT-116). Colorectal cancer is highly heterogeneous, and responses in a single cell line cannot be generalized. No additional colorectal cancer cell lines, patient-derived models, or in vivo studies are presented. The NCI 60-cell-line screen includes only a few colorectal lines, and the data for those are not fully reported.
- **Why it matters** Without evidence of activity across multiple colorectal cancer models, the claim that PQ2 is "effective in colorectal cancer treatment" is an overstatement. The manuscript does not establish that PQ2 has any selective advantage for colorectal cancer over other cancer types, nor does it address potential resistance mechanisms.
- **Resolution test** The authors should test PQ2 in at least 2-3 additional colorectal cancer cell lines (e.g., HT-29, SW480, Caco-2) and include a normal colonic epithelial cell line to demonstrate selectivity. Ideally, an in vivo xenograft study would strengthen the claim, but at minimum, multi-cell-line data with dose-response curves are required.

- **Concern ID** R1-M2
- **Severity** Major
- **Blocking** Yes
- **Axis** Statistical rigor and data reporting
- **Claim pointer** The authors report IC50 values and apoptosis percentages without providing statistical details.
- **Evidence pointer** Section 2.1.2, Section 2.1.3, Figure 8, Figure 9
- **Concern** The MTT assay results are reported as IC50 values with standard deviations, but no information is given on the number of independent experiments, number of replicates per experiment, or the statistical test used to determine significance (only a p-value threshold is mentioned). The apoptosis data are presented as percentages without error bars or statistical comparison. Figure 8 shows a graphical comparison but lacks error bars and significance markers.
- **Why it matters** Reproducibility and statistical validity are fundamental to the claims of significant cytotoxicity and apoptosis induction. Without proper statistical reporting, the reader cannot assess the reliability of the data or the validity of the comparisons to cisplatin.
- **Resolution test** The authors must provide full experimental details: number of independent biological replicates, number of technical replicates, and the specific statistical tests used (e.g., one-way ANOVA with post-hoc tests). All figures should include error bars and significance indicators. Raw data or a data availability statement should be provided.

- **Concern ID** R1-M3
- **Severity** Major
- **Blocking** Yes
- **Axis** Interpretation of in silico docking results
- **Claim pointer** The authors state that PQ2 "presented a key hydrogen bonding through its methoxy moiety" and that this explains its higher binding affinity to DNA, linking it to the observed biological activity.
- **Evidence pointer** Section 2.1.3, Figure 10, Table 3
- **Concern** The docking study is presented as evidence of DNA binding, but the methodology is described in only one sentence. No docking scores are provided in the text (only a range in Table 3), and the significance of the hydrogen bond is not contextualized. The claim that the docking results are "consistent with the biological data" is not quantitatively supported. Furthermore, the biological relevance of minor-groove binding for this compound is not established experimentally.
- **Why it matters** The authors use the docking results to propose a mechanism of action (DNA binding leading to apoptosis). If the docking is not robustly validated, this mechanistic claim is speculative. Overinterpretation of docking results without experimental validation (e.g., DNA binding assays, gel shift, or fluorescence intercalation) weakens the overall argument.
- **Resolution test** The authors should provide a more detailed description of the docking protocol, including validation of the docking method (e.g., redocking of a known ligand, RMSD values). Docking scores for all compounds should be reported. Most importantly, an experimental DNA binding assay (e.g., UV-vis titration, circular dichroism, or gel electrophoresis) should be performed to support the in silico predictions.

- **Concern ID** R1-M4
- **Severity** Major
- **Blocking** Yes
- **Axis** Apoptosis assay completeness
- **Claim pointer** The authors state that PQ2 "significantly induced apoptosis in HCT-116 cells compared to cisplatin" based on annexin V/ethidium homodimer III staining.
- **Evidence pointer** Section 2.1.3, Figure 9
- **Concern** The apoptosis assay is described briefly, and the results are presented as a single percentage at one time point (12 h). No information is provided on the concentration of PQ2 used for this assay (presumably the IC50, but this is not stated), the gating strategy for flow cytometry (if used), or whether the assay was performed in a blinded manner. The distinction between early apoptosis, late apoptosis, and necrosis is not clearly explained in the context of the results.
- **Why it matters** Apoptosis induction is a central claim of the manuscript. If the assay is not rigorously described and quantified, the claim is not verifiable. The comparison to cisplatin is also limited to a single time point, which may not capture the full dynamics of cell death.
- **Resolution test** The authors should provide a detailed protocol for the apoptosis assay, including concentrations, time points, and quantification method. Representative fluorescence images should be shown. Ideally, a time-course experiment and a secondary method (e.g., caspase-3/7 activity assay or Western blot for cleaved PARP) should be included to confirm apoptosis.

- **Concern ID** R1-M5
- **Severity** Major
- **Blocking** No
- **Axis** ADME predictions and drug-likeness claims
- **Claim pointer** The authors claim that PQ2 possesses "orally bioavailable drug-like properties" based on in silico ADME predictions.
- **Evidence pointer** Section 2.2, Section 3
- **Concern** The ADME predictions are based solely on computational tools (QikProp) and are presented as definitive. No experimental validation (e.g., Caco-2 permeability, microsomal stability, plasma protein binding) is provided. The claim of oral bioavailability is particularly strong and cannot be supported by in silico data alone.
- **Why it matters** The therapeutic potential of PQ2 is partly based on its predicted pharmacokinetic profile. If these predictions are not validated, the claim of drug-likeness is premature and could mislead readers.
- **Resolution test** The authors should temper their claims regarding oral bioavailability and drug-likeness, clearly stating that these are predictions that require experimental confirmation. If possible, include experimental ADME data or at least acknowledge the limitations of in silico predictions.

### Minor Comments

- **Concern ID** R1-m1
- **Severity** Minor
- **Axis** Clarity of structure-activity relationship discussion
- **Affected element** Section 3, Discussion
- **Evidence pointer** Section 3
- **Issue** The discussion of structure-activity relationships is brief and does not systematically compare PQ2, PQ3, and PQ10 in terms of their structural differences and how these relate to activity. The statement that "the addition of the methoxy substitution to the anilino group led to a decrease in the anticancer activity" is not fully explained.
- **Required correction** Provide a more detailed structure-activity relationship analysis, possibly with a table summarizing structural features and corresponding activities across the series.

- **Concern ID** R1-m2
- **Severity** Minor
- **Axis** Figure quality and labeling
- **Affected element** Figures 5-7, Figure 8, Figure 9
- **Evidence pointer** Section 2.1.1, Section 2.1.2, Section 2.1.3
- **Issue** The figures are referenced but not described in detail in the text. It is unclear what exactly is plotted in Figures 5-7 (mean growth percent for each cell line) and whether the data are presented as bar graphs or heat maps. Figure 8 lacks error bars and significance markers. Figure 9 is not described in sufficient detail.
- **Required correction** Ensure all figures are self-explanatory with clear axis labels, legends, and error bars where applicable. Add a brief description of each figure in the text.

- **Concern ID** R1-m3
- **Severity** Minor
- **Axis** Reference to previous work
- **Affected element** Section 1, Introduction; Section 4.1, Chemistry
- **Evidence pointer** Section 1, Section 4.1
- **Issue** The authors reference their previous work on the synthesis and evaluation of PQ analogs but do not provide specific citation details in the text provided. The chemistry section states that synthetic protocols were reported previously, but no reference is given.
- **Required correction** Add appropriate citations to previous publications for the synthesis and prior biological evaluation of the compounds.

- **Concern ID** R1-m4
- **Severity** Minor
- **Axis** Language and terminology
- **Affected element** Throughout
- **Evidence pointer** Abstract, Section 3
- **Issue** Some phrases are awkward or imprecise, e.g., "Plants have paved the way for the attainment of molecules" and "the most important point to emerge from this study." The term "drug-like" is used without clear definition.
- **Required correction** Revise for clarity and precision. Define "drug-like" in the context of the study.

- **Concern ID** R1-m5
- **Severity** Minor
- **Axis** Conclusion overstatement
- **Affected element** Section 5, Conclusions
- **Evidence pointer** Section 5
- **Issue** The conclusion states that "this is the first study showing the anti-colorectal cancer activity of PQ analogs." This claim is difficult to verify and is not supported by a comprehensive literature review in the manuscript.
- **Required correction** Soften this claim or provide a thorough literature search to substantiate it.

## Risk / unsupported claims
- The claim that PQ2 is "effective in colorectal cancer treatment" is unsupported by the limited in vitro data in a single cell line.
- The claim that PQ2 induces apoptosis is based on a single assay at a single time point without statistical validation.
- The claim that PQ2 binds to DNA in the minor groove and that this explains its activity is based solely on docking predictions without experimental validation.
- The claim that PQ2 possesses "orally bioavailable drug-like properties" is based solely on in silico predictions and is not experimentally verified.
- The claim of being the "first study showing anti-colorectal cancer activity of PQ analogs" is not substantiated.
- The NCI 60-cell-line screening data are only partially reported, and the full dataset is not available for assessment.
- The selectivity of PQ2 for cancer cells over normal cells is claimed but not demonstrated in this study (the PBMC data referenced are from previous work).